In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Global Blood Therapeutics (GBT), with a price target of $83.00. The company’s shares closed last Monday at $46.46.
According to TipRanks.com, Baral is a 5-star analyst with an average return of 18.5% and a 41.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, Madrigal Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
Global Blood Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $97.50, implying an 116.4% upside from current levels. In a report issued on October 4, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on Global Blood Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $57.32 million. In comparison, last year the company had a GAAP net loss of $43.07 million.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GBT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.
